Larimar Therapeutics (LRMR) Non Operating Income (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Non Operating Income for 14 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income fell 2.55% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $6.5 million (down 25.88% YoY), and the FY2025 full-year result was $6.8 million, down 33.66% from the prior year.
• Non Operating Income improved to $1.6 million in Q2 2026 per LRMR's latest filing, from $1.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.0 million in Q2 2024 and bottomed at -$56000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $1.5 million across 5 years, with a median of $1.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income tumbled 411.11% in 2022, then jumped 6170.0% in 2023.
• Over 5 years, Non Operating Income stood at $1.0 million in 2022, then advanced by 15.29% to $1.2 million in 2023, then surged by 111.21% to $2.5 million in 2024, then tumbled by 38.44% to $1.5 million in 2025, then rose by 3.22% to $1.6 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $1.6 million, $1.5 million, and $1.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.